BiotechTube

CP-866,087 + CP-866,087 + CP-866,087 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sexual Dysfunction, Physiological

Conditions

Sexual Dysfunction, Physiological

Trial Timeline

Jul 1, 2007 → Oct 1, 2008

NCT ID
NCT00482664

About CP-866,087 + CP-866,087 + CP-866,087 + Placebo

CP-866,087 + CP-866,087 + CP-866,087 + Placebo is a phase 2 stage product being developed by Pfizer for Sexual Dysfunction, Physiological. The current trial status is completed. This product is registered under clinical trial identifier NCT00482664. Target conditions include Sexual Dysfunction, Physiological.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT00482664Phase 2Completed
NCT00479492Phase 2Completed

Competing Products

18 competing products in Sexual Dysfunction, Physiological

See all competitors
ProductCompanyStageHype Score
DapoxetineJohnson & JohnsonPhase 3
77
Gardasil VaccineMerckPre-clinical
23
sildenafilPfizerApproved
84
sildenafilPfizerPhase 2
51
PF-00446687 + PlaceboPfizerPhase 2
51
BremelanotidePfizerPhase 2
51
Sildenafil 100 mg + PlaceboPfizerPhase 2
51
AlfuzosinSanofiApproved
84
AVANAFIL + placeboSanofiPhase 3
76
Levitra (Vardenafil, BAY38-9456) + PlaceboBayerApproved
82
Placebo + 0.5 mgTestosterone + 10 mg BuspironeBrain BiotechPhase 2
44
Placebo + Testosterone + Buspirone hydrochlorideBrain BiotechPhase 2
44
Placebo + Sildenafil + TestosteroneBrain BiotechPhase 2
44
tibolone + estradiol-norethisteroneOrganonPhase 3
72
Bremelanotide + PlaceboPalatin TechnologiesPhase 3
69
bremelanotidePalatin TechnologiesPhase 2
44
BremelanotidePalatin TechnologiesPhase 3
69
EVO100 + PlaceboEvofem BiosciencesPhase 3
69

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84